Clinical Report: Anakinra in Febrile Infection-Related Epilepsy Syndrome
Overview
This case report highlights the successful use of anakinra in a pediatric patient with febrile infection-related epilepsy syndrome (FIRES) who was resistant to tocilizumab. Despite normal IL-1β levels, anakinra administration led to rapid seizure control and improved clinical outcomes.
Background
Febrile infection-related epilepsy syndrome (FIRES) is a severe condition characterized by super-refractory status epilepticus following a febrile illness, with limited treatment options available. Neuroinflammation, particularly involving cytokines like IL-1β and IL-6, plays a critical role in the pathophysiology of FIRES. The sequential use of IL-6 receptor blockade followed by IL-1 receptor blockade is not well-documented, especially in cases with normal IL-1β levels.
Data Highlights
No numerical data available in the article.
Key Findings
Anakinra was effective in controlling seizures in a child with FIRES resistant to tocilizumab.
The patient had normal IL-1β levels, challenging the assumption that elevated IL-1β is necessary for anakinra efficacy.
Initial treatment with tocilizumab showed temporary improvement, but seizures relapsed, necessitating a switch to anakinra.
The patient achieved seizure control within five days of starting anakinra and was discharged with mild cognitive dysfunction.
At one-month follow-up, the patient experienced rare brief seizures and was able to attend school.
Clinical Implications
Discuss potential risks or considerations for clinicians when using anakinra in patients with normal IL-1β levels.
Conclusion
This case underscores the importance of considering anakinra for refractory FIRES, highlighting its potential effectiveness regardless of IL-1β biomarker status.
